CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$51.11 USD
-3.74 (-6.82%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $51.14 +0.03 (0.06%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
CRSP 51.11 -3.74(-6.82%)
Will CRSP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRSP
Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised
Gilead Sciences (GILD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates
Other News for CRSP
Vertex Pharmaceuticals (NASDAQ:VRTX) Slides despite Raising Revenue Guidance
Vertex boosts revenue forecast on back of cystic fibrosis franchise growth
JMP Securities healthcare analysts hold an analyst/industry conference call
The Top 3 Cathie Wood Stocks to Buy Now: Summer 2024
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q2 2024 Update